TNFRSF17 and Miyoshi myopathy: Thus, the anti-BCMA CAR Vγ9Vδ2 T cell treatment prolonged median survival by 69% and 34%, respectively, as compared to the PBS and Ctrl CAR groups, significantly delaying disease progression in MM tumor-bearing mice.